If you attended the meeting, click here to claim your CE Credit

Presentations

Click the links below to view our presentations:

Molecular Landscape of MDS and its Clinical Implications
Elli Papaemmanuil, PhD
Memorial Sloan Kettering

Pathogenetic Features of Hematopoiesis in MDS: Focus on Aging
Irving L. Weissman, MD
Stanford University School of Medicine

CMML: From Biology to Treatment
Pierre Fenaux, MD, PhD
Hôpital St. Louis
Paris VII Univertisy

Therapeutic Options after First Line Treatment Failure
Guillermo Garcia-Manero, MD
University of Texas
MD Anderson Cancer Center

Allogeneic Hematopoietic Stem Cell Transplantation in MDS: ELN/US Recommendations
Theo de Witte, MD, PhD
Radboud University Medical Center
Radboud Institute of Molecular Life Sciences

Program Overview

Recent developments in defining the implications of molecular mutations and miRNA abnormalities, pathogenetic features as they relate to aging, and options for hematopoietic stem cell transplantation have generated valuable advances for aiding management of patients with myelodysplastic syndromes (MDS). These important topics will be discussed during this symposium. The unique nature of CMML as a subset of MDS/MPN will be reviewed, as will a number of the newer treatment approaches for patients whose disease has failed to respond to initial therapies.

Target Audience

This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

• Describe molecular and biologic features which are useful for classifying MDS and aiding in therapeutic decision-making
• Describe some newer condition regimens available and their selections for MDS patients
• Describe alternative treatment approaches for patients whose disease has failed to respond to first line therapy
• Describe the differences in molecular findings and treatment options for CMML

Featured Faculty

Theo J.M. de Witte, MD, PhD

Professor of Hematology
Radboud University Medical Center
Radboud Institute of Molecular Life Sciences
Nijmegen, The Netherlands

Pierre Fenaux, MD, PhD

Professor of Hematology
Hôpital Saint Louis
Paris VII University
Paris, France

Guillermo Garcia-Manero, MD

Professor of Medicine
Chief, Section of Myelodysplastic Syndromes
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elli Papaemmanuil, PhD

Assistant Member
Epidemiology and Biostatistics
Center of Molecular Oncology
Memorial Sloan Kettering
New York City, New York

Irving L. Weissman, MD

Stanford University School of Medicine
Director, Institute for Stem Cell Biology and Regenerative Medicine
Director, Stanford Ludwig Center for Cancer Stem Cell Research and Medicine
Professor of Pathology and Developmental Biology
Stanford, California